254732-51-9

Basic information

• Product Name: 2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE
• Synonyms: 2-Chloro-3-(trifluoromethyl)-1,4-benzodiazine;CBDivE_012686;ST5407629;ZINC00158118
• CAS NO: 254732-51-9
• Molecular Formula: C₉H₄ClF₃N₂
• Molecular Weight: 232.5938
• Mol File: 254732-51-9.mol

Chemical Properties

• Boiling Point: 251.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.496±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -5.42±0.48(Predicted)
• CAS DataBase Reference: 2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE(254732-51-9)
• EPA Substance Registry System: 2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE(254732-51-9)

Safety Data

• Hazardous Substances Data: 254732-51-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE is used as a building block for the synthesis of various biologically active compounds, contributing to the development of new pharmaceuticals with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE is utilized as a precursor for the synthesis of bioactive compounds, which can be further developed into agrochemicals for crop protection and other agricultural applications.
Used in Organic Synthesis:
2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE is employed as a reagent in organic synthesis, facilitating the creation of new chemical entities and compounds with diverse applications.
Used in Material Development:
This chemical compound is used in the development of new materials, leveraging its unique properties due to the presence of chlorine and trifluoromethyl groups, which can enhance the performance and characteristics of the resulting materials.
Used in Research and Development:
2-CHLORO-3-(TRIFLUOROMETHYL)QUINOXALINE is utilized in research and development settings to explore its potential applications and properties, further expanding its use in various industries and scientific fields.

Upstream product

• 58457-64-0 3-(trifluoromethyl)quinoxalin-2(1H)-one 
• 58457-64-0 3-(trifluoromethyl)quinoxalin-2-ol 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 1225651-99-9 4-(3-(trifluoromethyl)quinoxalin-2-yl)phenol 
• 111269-69-3 2-(p-tolyl)-3-(trifluoromethyl)quinoxaline 

Relevant articles and documents

Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum

The identification of a plant-like Achille's Heel relict, i.e. the apicoplast, that is essential for Plasmodium spp., the causative agent of malaria lead to an attractive drug target for new antimalarials with original mechanism of action. Although it is not photosynthetic, the apicoplast retains several anabolic pathways that are indispensable for the parasite. Based on previously identified antiplasmodial hit-molecules belonging to the 2-trichloromethylquinazoline and 3-trichloromethylquinoxaline series, we report herein an antiplasmodial Structure-Activity Relationships (SAR) study at position two of the quinoxaline ring of 16 newly synthesized compounds. Evaluation of their activity toward the multi-resistant K1 Plasmodium falciparum strain and cytotoxicity on the human hepatocyte HepG2 cell line revealed a hit compound (3k) with a PfK1 EC50 value of 0.3 μM and a HepG2 CC50 value of 56.0 μM (selectivity index = 175). Moreover, hit-compound 3k was not cytotoxic on VERO or CHO cell lines and was not genotoxic in the in vitro comet assay. Activity cliffs were observed when the trichloromethyl group was replaced by CH3, CF3 or H, showing that this group played a key role in the antiplasmodial activity. Biological investigations performed to determine the target and mechanism of action of the compound 3k strongly suggest that the apicoplast is the putative target as showed by severe alteration of apicoplaste biogenesis and delayed death response. Considering that there are very few molecules that affect the Plasmodium apicoplast, our work provides, for the first time, evidence of the biological target of trichloromethylated derivatives.

Visible Light-Induced Photocatalytic C?H Perfluoroalkylation of Quinoxalinones under Aerobic Oxidation Condition

An efficient approach using a photocatalytic strategy for C?H perfluoroalkylation of quinoxalinones under aerobic oxidation condition has been developed. Such transformation employs readily available sodium perfluoroalkanesulfinates as perfluoroalkylation reagents and demonstrates good functional group compatibility, affording corresponding products in moderate to good yields. Compared with previous procedures, this protocol uses oxygen as oxidant, and avoids the use of external additive. A radical mechanism is involved in this perfluoroalkylation reaction. (Figure presented.).

Synthesis of new 2-substituted 3-(tri(di)fluoromethyl)-quinoxalines from 3-(trifluoromethyl)quinoxalin-2(1H)-oneand 3-(tri(di)fluoromethyl)quinoxaline-2-carboxylic acids

[Figure not available: see fulltext.] Starting from 3-(trifluoromethyl)quinoxalin-2(1H)-one, a wide range of new 2-substituted 3-(trifluoromethyl)quinoxalines were obtained, including amino, bromo, chloro, hydrazino, phenyl, α-furyl, formyl, methylsulfanyl, and methylsulfonyl derivatives. 3-(Tri(di)-fluoromethyl)quinoxaline-2-carboxylic acids were obtained for the first time and used for the synthesis of 2-amino-3-(tri(di)-fluoromethyl)quinoxalines and 2-(2-aminothiazol-4-yl)-3-(trifluoromethyl)quinoxaline.

QUINOXALINE-BASED LXR MODULATORS

Disclosed are quinoxaline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): wherein: each of L1 and L2 is, independently, a bond, —O— or —NH—;R2 is C6/

Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo

Using a previously reported flexible alignment model we have designed, synthesized, and evaluated a series of compounds at the human histamine H 4 receptor (H4R) from which 2-(4-methyl-piperazin-l-yl)- quinoxaline (3) was identified as a new lead structure for H4R ligands. Exploration of the structure-activity relationship (SAR) of this scaffold led to the identification of 6,7-dichloro 3-(4-methylpiperazin-l-yl) quinoxalin-2(1H)-one (VUF 10214, 57) and 2-benzyl-3-(4-methyl-piperazin-l-yl) quinoxaline (VUF 10148, 20) as potent H4R ligands with nanomolar affinities. In vivo studies in the rat reveal that compound 57 has significant anti-inflammatory properties in the carrageenan-induced paw-edema model.